Jefferies downgraded Myriad Genetics to Underperform from Hold with a price target of $20, down from $25, after assuming coverage of the name. The firm believes “durable growth stories” in the life sciences and diagnostic tools group with operating leverage, healthy free cash flow and balance sheet optionality “should be rewarded.” The analyst sees a host of headwinds for growth tools and awaits more visibility, and is upbeat on the secular growth drivers in the diagnostics space. Recent survey works points to muted next generation sequencing and proteomics budgets, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
- Myriad Genetics and Qiagen to co-develop HRD test
- Qiagen, Myriad Genetics to develop kit-based test for analyzing HRD status
- Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
- New Study Published in JCO Precision Oncology Shows Myriad Genetics’ Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer